7 results about "Channel modulator" patented technology

The present invention provides, inter alia, apelin receptor agonists having increased half-life, reduced desensitization, improved apelin receptor signaling properties (e.g., bias of G a signaling over arrestin signaling), enhanced stability, and / or enhanced binding to apelin receptors.

Fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition related to aberrant function of voltage-gated sodium ion channels, e.g., an abnormal, delayed / persistent sodium current. Treatment methods for a disease or condition related to aberrant function of sodium ion channels are also provided herein, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders.

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

The application discloses a use of patchouli oil or patchouli alcohol in preparation of a TRP channel modulator. The patchouli oil or patchouli alcohol has a function of regulating a TRP channel, and particularly has a synergistic effect with a TRPM2 inhibitor in anti-inflammatory effect, and is a promising TRPM2 inhibitor. In addition, the patchouli alcohol or patchouli oil has a function of improving colitis-related injury, and can inhibit expression of IL-1beta, TNF-alpha, IL-6, TRPM2, TRPM6 and TRPM7 genes.